The short version
20 companies supply this market — deep enough that no single failure threatens the supply.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Methotrexate
methotrexate · METHOTREXATE SODIUM 2.5 mg/1 · Tablet · Oral · Safecor Health LLC
NDC 48433-0065-05 · 20 BLISTER PACK in 1 CARTON / 1 TABLET in 1 BLISTER PACK · ANDA · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 16729-0486-01) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$0.4149per unit
middle half $0.2110–$0.5609 · 5,496 plans · Apr 1, 2026
Est. net of rebatesⓘ
≈ $0.4149
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
100%of plans cover it
tier 2 · prior auth 24% · step therapy 3% · qty limit 0%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for methotrexate (oral solid) in the next 90 days
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $1,035.57 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- ANDA081235
- TE code
- AB
- Approval date
- May 15, 1992
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of methotrexate (Tablet)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Bryant Ranch Prepack | METHOTREXATE SODIUM 2.5 mg/1 | Jul 15, 2026 | Sep 3, 2026 |
| A-S Medication Solutions | METHOTREXATE SODIUM 2.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Accord Healthcare Inc. | METHOTREXATE SODIUM 2.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Alembic Pharmaceuticals Inc. | METHOTREXATE SODIUM 2.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Alembic Pharmaceuticals Limited | METHOTREXATE SODIUM 2.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Aurobindo Pharma Limited | METHOTREXATE SODIUM 2.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| AvKARE | METHOTREXATE SODIUM 2.5 mg/1 | Jul 29, 2026 | Sep 2, 2026 |
| AvPAK | METHOTREXATE 2.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Chartwell RX, LLC | METHOTREXATE SODIUM 2.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Coupler LLC | METHOTREXATE SODIUM 2.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Golden State Medical Supply, Inc. | METHOTREXATE SODIUM 2.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Major Pharmaceuticals | METHOTREXATE 2.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Mylan Institutional Inc. | METHOTREXATE SODIUM 2.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Mylan Pharmaceuticals Inc. | METHOTREXATE SODIUM 2.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Proficient Rx LP | METHOTREXATE SODIUM 2.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Safecor Health LLC | METHOTREXATE SODIUM 2.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Teva Pharmaceuticals USA, Inc. | METHOTREXATE SODIUM 2.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Lifesciences Limited | METHOTREXATE 2.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Pharmaceuticals USA Inc. | METHOTREXATE 2.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| NuCare Pharmaceuticals, Inc. | METHOTREXATE SODIUM 2.5 mg/1 | Jul 15, 2026 | Aug 28, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Methotrexate — NDC 48433-0065-05," retrieved September 3, 2026, https://drugdashboards.com/drug/48433006505.
Free to cite with attribution — see how the data is put together.